Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.

ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Assessing potential formulation and manufacturing issues in early development phases can improve a drug’s chances for success.

Can Early Development Strategies Avoid Later-Stage Disasters?

Jasdip S. Koner is senior formulation scientist at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

David A. Wyatt is chief operating officer at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

Eman Z. Dahmash is chief scientific officer at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

Afzal Mohammed is chief technical officer at Aston Particle Technologies Ltd., Aston University, Birmingham, United Kingdom.

Aston Particle Technologies has developed a technology that produces functionalized particles in a one-step, environmentally friendly process.

Dry Particle Coating—A Unique Solution for Pharmaceutical Formulation

Regis Cazes is strategic marketing director at Medelpharm, France, a company creating the STYL’One family of tableting instruments and providing contract lab services in powder characterization and tableting; rcazes@medelpharm.com.

Tableting instruments (i.e., compaction simulators) that simulate high-speed presses can be used in a quality-by-design (QbD) approach to perform in-depth material characterization and direct scale-up.

A QbD Approach to Shorten Tablet Development Time

Peter Scholes is chief scientific officer at Quotient Sciences.

Integration of formulation development, real-time adaptive GMP manufacturing, and clinical testing using a consumer preference panel can save time and cost in performing taste-masking assessments.

Removing the Bitter Taste from Drug Development

The company is voluntarily recalling three lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial and one lot of Labetalol Hydrochloride Injection, USP, Novaplus because of the potential of cracked glass at the rim of the vials.

Hospira Recalls Labetalol Hydrochloride Due to Cracked Vials

Colorcon's Opadry EZ provides superior slip and significantly reduces the probability of the tablet sticking to the throat or esophagus.

A New Coating System to Ease Swallowability

Fluarix Tetra has been approved for use in children aged six months and above.

GSK's Influenza Vaccine Gets EU Nod for Expanded Indication

Unlike current approaches where bioconjugation is typically done following the manufacture of the monoclonal antibody and the cytotoxic drug, the new method begins with the antibody supernatants and eliminates the need for extensive chromatographic purification. 

ADC Bio to Develop New Bioconjugation Process

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Gottlieb promoted the development of biosimilars and safer opioid packaging at a briefing sponsored by Alliance for a Stronger FDA and the Pew Charitable Trusts.